Insider Trading Alert - ASH, ABC And IART Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 12, 2015, 114 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $4,322,819.24.

Highlighted Stocks Traded by Insiders:

Ashland (ASH) - FREE Research Report

Fernandez-Moreno Luis M, who is Senior Vice President at Ashland, sold 1,300 shares at $132.00 on May 12, 2015. Following this transaction, the Senior Vice President owned 39,351 shares meaning that the stake was reduced by 3.2% with the 1,300-share transaction.

The shares most recently traded at $125.94, down $6.06, or 4.81% since the insider transaction. Historical insider transactions for Ashland go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 16,951
  • 24-Week # shares sold: 38,069

The average volume for Ashland has been 562,700 shares per day over the past 30 days. Ashland has a market cap of $8.9 billion and is part of the basic materials sector and chemicals industry. Shares are up 9.82% year-to-date as of the close of trading on Tuesday.

Ashland Inc. operates as a specialty chemicals company worldwide. The company's Specialty Ingredients segment provides products, technologies, and resources for solving formulation and product-performance challenges. The stock currently has a dividend yield of 1.03%. The company has a P/E ratio of 52.0. Currently, there are 8 analysts who rate Ashland a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASH - FREE

TheStreet Quant Ratings rates Ashland as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Ashland Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AmerisourceBergen (ABC) - FREE Research Report

Guttman Tim G., who is Chief Financial Officer at AmerisourceBergen, sold 16,022 shares at $115.25 on May 12, 2015. Following this transaction, the Chief Financial Officer owned 9,472 shares meaning that the stake was reduced by 62.85% with the 16,022-share transaction.

The shares most recently traded at $114.75, down $0.50, or 0.44% since the insider transaction. Historical insider transactions for AmerisourceBergen go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 1,400
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 1,400
  • 24-Week # shares bought: 4,000
  • 24-Week # shares sold: 13,877

The average volume for AmerisourceBergen has been 1.9 million shares per day over the past 30 days. AmerisourceBergen has a market cap of $25.2 billion and is part of the services sector and wholesale industry. Shares are up 27.45% year-to-date as of the close of trading on Tuesday.

AmerisourceBergen Corporation sources and distributes pharmaceutical products to healthcare providers, pharmaceutical and biotech manufacturers, and specialty drug patients in the United States and internationally. The stock currently has a dividend yield of 1.01%. Currently, there are 8 analysts who rate AmerisourceBergen a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABC - FREE

TheStreet Quant Ratings rates AmerisourceBergen as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and revenue growth. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full AmerisourceBergen Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Integra Lifesciences Holdings (IART) - FREE Research Report

Leonetti Deborah A, who is Corp VP, Glbl Servs & Repair at Integra Lifesciences Holdings, sold 2,000 shares at $64.82 on May 12, 2015. Following this transaction, the Corp VP, Glbl Servs & Repair owned 8,715 shares meaning that the stake was reduced by 18.67% with the 2,000-share transaction.

The shares most recently traded at $65.33, up $0.51, or 0.78% since the insider transaction. Historical insider transactions for Integra Lifesciences Holdings go as follows:

  • 4-Week # shares sold: 3,500
  • 12-Week # shares sold: 3,500
  • 24-Week # shares sold: 3,500

The average volume for Integra Lifesciences Holdings has been 194,700 shares per day over the past 30 days. Integra Lifesciences Holdings has a market cap of $2.1 billion and is part of the health care sector and health services industry. Shares are up 20.1% year-to-date as of the close of trading on Tuesday.

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery; U.S. Extremities; U.S. The company has a P/E ratio of 53.8. Currently, there are 6 analysts who rate Integra Lifesciences Holdings a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IART - FREE

TheStreet Quant Ratings rates Integra Lifesciences Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Integra Lifesciences Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home